Europe Bladder Cancer Diagnostics Market To Reach $1.33 Billion By 2030

Europe Bladder Cancer Diagnostics Market Growth & Trends

The Europe bladder cancer diagnostics market size is expected to reach USD 1.33 billion by 2030, registering a CAGR of 8.38% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of bladder cancer, advancements in diagnostic technologies such as liquid biopsy and urine-based tests, and rising awareness about early cancer detection contribute significantly to market growth. Additionally, supportive government initiatives and growing healthcare expenditure further propel the demand for advanced diagnostics. The aging population in Europe, coupled with lifestyle factors such as smoking and exposure to carcinogens, also boosts the need for timely and accurate bladder cancer diagnostics. The market is expected to continue expanding with technological innovations.

Non-muscle Invasive Bladder Cancer (NMIBC) remains a significant global health issue, with nearly half of the diagnosed cases experiencing recurrences or progression to Muscle-invasive Bladder Cancer (MIBC). Factors contributing to this include misdiagnosis, delays in diagnosis, and incomplete tumor resection. Missing early recurrence of high-risk lesions in NMIBC can significantly delay appropriate treatments, negatively impacting disease prognosis.

Accurate and timely diagnosis of NMIBC is critical for proper risk stratification, decision-making, and treatment planning. Precision diagnostics rely on clinical presentation and traditional risk factors and provide deeper insights into the genetic and molecular characteristics of tumors, identifying potential drivers of aggressive behavior. Combining conventional diagnostics such as radiology and cystoscopy with emerging technologies-such as next-generation imaging, immunohistochemical biomarkers, Next-Generation Sequencing (NGS), multi-omics, and AI/machine learning-has the potential to improve diagnostic precision, leading to more effective and cost-efficient care.

In NMIBC, AI is increasingly being studied in clinical trials. One tool recently evaluated in a clinical study uses comprehensive molecular profiling to assess pre- and post-treatment responses to BCG immunotherapy. The aim is to create personalized models for predicting treatment response. Another tool, PROGRxN-BCa, presented at the 2024 AUA Congress, outperformed current methods in predicting disease progression, helping avoid unnecessary treatment escalation. A systematic review of AI in NMIBC also found that AI models outperformed traditional methods in predicting outcomes.

Despite these advancements, challenges remain in implementing precision diagnostics more widely. Limited high-quality clinical data, lack of guideline recommendations, high equipment costs, and regulatory hurdles are significant barriers. Collaboration between healthcare professionals and AI developers is crucial for building better models and advancing NMIBC care to the next level.

In 2024, the World Bladder Cancer Patient Coalition (WBCPC) and the European Association of Urology (EAU) are launching a White Paper on Bladder Cancer. Aimed at EU and national policymakers, this advocacy resource addresses key challenges faced by patients and caregivers, offering recommendations to improve bladder cancer care. The White Paper also seeks to raise awareness among policymakers in light of Europe's Beating Cancer Plan and the upcoming 2024 EU elections. The goal is to inspire policy actions focused on addressing neglected cancers like bladder cancer and closing gaps in cancer care by ensuring access to timely, accurate diagnosis and high-quality treatment.

 Request a free sample copy or view report summary: Europe Bladder Cancer Diagnostics Market Report

Europe Bladder Cancer Diagnostics Market Report Highlights

• Based on technology, cystoscopy accounted for the largest revenue share of 47.54% in 2023. Cystoscopy is a key diagnostic technology in the Europe bladder cancer diagnostics market, enabling direct visualization of the bladder. Its integration with other diagnostic modalities enhances early detection and monitoring, contributing to market growth

• Based on cancer type, transitional cell bladder dominated the market and accounted for the largest share of 87.39% in 2023.Transitional Cell Bladder Cancer (TCBC) holds a significant market share in the European bladder cancer diagnostics market, as it represents over 90% of bladder cancer cases in the region. Its predominance drives the need for advanced diagnostic methods to improve early detection and treatment outcomes. The market's growth reflects a focus on comprehensive diagnostic approaches, including cystoscopy, molecular testing, and imaging, essential for accurate detection & staging of TCBC. The emphasis on these methods is crucial for addressing the high incidence rates and optimizing patient management strategies in Europe

• Based on end use, hospital settings dominated the market with the largest share of 75.51% in 2023. This reflects the significant reliance on hospitals for advanced diagnostic procedures and treatments

• The non-hospital settings segment is expected to experience the fastest growth, driven by an anticipated CAGR of 8.99% over the forecast period. This growth is likely due to the increasing availability of diagnostic technologies in outpatient clinics, private labs, and home-based testing, enabling broader access to diagnostics outside traditional hospital environments and catering to patient demand for more convenient options

• Germany dominated the Europe bladder cancer diagnostics market. The German market is expanding with key advancements. Key player contribution in enhancing patient care and communication, setting the stage for future market growth. The European uCAIR project’s funding aims to revolutionize biopsy analysis with rapid, AI-integrated Raman imaging, improving diagnostic speed and accuracy 

Europe Bladder Cancer Diagnostics Market Segmentation

Grand View Research has segmented the Europe bladder cancer diagnostics market based on technology, cancer type, end-use, and region:

Europe Bladder Cancer Diagnostics Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Cystoscopy

• Ultrasound

• Urinalysis

• Others

Europe Bladder Cancer Diagnostics Cancer Type Outlook (Revenue, USD Million, 2018 - 2030)

• Transitional Cell Bladder Cancer

• Squamous Cell Bladder Cancer

• Others

Europe Bladder Cancer Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Settings

• Non Hospital Settings

Europe Bladder Cancer Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

  • Poland

  • Finland

  • Estonia

  • Latvia

  • Lithuania

  • Portugal

  • The Netherlands

  • Rest of Europe

List of Key Players in the Europe Bladder Cancer Diagnostics Market

• Abbott

• Nucleix

• Danaher Corporation

• Pacific Edge

• Polymedco, LLC.

• KARL STORZ

• AroCell (IDL Biotech)

• Micromedic Technologies

• Sysmex Corporation.

• Vesica Health